Granalix BioTechnologies

Company Overview

Snapshot

Founded in May 2013, Granalix BioTechnologies operates with 1–10 employees. The company focuses on developing natural antioxidant products. In August 2020, studies highlighted the potential of GranaGard, its pomegranate-based supplement, in slowing neurodegenerative diseases.

Business overview

Granalix BioTechnologies develops science-based formulations of natural antioxidants for the prevention and treatment of neurodegenerative conditions. Its core product, GranaGard, is a submicron self-emulsion formulation of pomegranate seed oil, rich in punicic acid (PA). This formulation is designed to convert into conjugated linoleic acid, a known neuroprotector and mitochondrial activity modulator. The company operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals, and aims to serve markets globally, including Portugal, Israel, Greece, and Mexico.

Strategic signal

In August 2020, studies demonstrated that Granalix BioTechnologies' pomegranate supplement, GranaGard, showed promise in slowing neurodegenerative diseases. This indicates potential for the company's product to address significant health challenges, validating its research and development efforts in the health tech and life sciences sector.

Company Intelligence Q&A

What is Granalix BioTechnologies' primary product?

Granalix BioTechnologies' primary product is GranaGard, a submicron self-emulsion formulation of pomegranate seed oil designed to support brain health.

When was Granalix BioTechnologies founded?

Granalix BioTechnologies was founded in May 2013.

What is the key ingredient in GranaGard?

GranaGard contains high concentrations of punicic acid (PA) from pomegranate seed oil, which converts into conjugated linoleic acid, a neuroprotector.

What potential health benefits has GranaGard shown?

Studies in August 2020 indicated that GranaGard was shown to delay disease onset in a mouse model of genetic prion disease and reduce disease burden in a mouse model of multiple sclerosis.

In which markets does Granalix BioTechnologies operate?

Granalix BioTechnologies operates in global markets, including Portugal, Israel, Greece, and Mexico.